Scientific Programme
12:30
Welcome
Session 1: From basic science to clinical application
Chair: Jan B. Vermorken (BE)
13:00
The gut microbiota and anticancer immunotherapy
Laurence Zitvogel (F)
13:25
The bidirectional communication between tumor cells and other components of the tumor microenvironment
Phil Sloan (UK)
13:50
Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this
Kirsten Lauber (DE)
14:15
DNA repair mechanisms as a new target in head and neck cancer
Kevin Harrington (UK)
14:40
Coffee break
15:10
How to standardize molecular profiling programs for routine patient care
Ingeborg Tinhofer (DE)
15:35
Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer
Christophe Le Tourneau (F)
16:00
Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches
Ben O’Leary (UK)
16:25
Proffered paper session
Chaired by René Leemans
17:30
18:30
News form the EHNS
Wojciech Golusinski, President EHNS
19:00
Welcome reception
Session 2: Primary disease
Chair Piero Nicolai (I)
09:00
Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neck cancer
Brian O’Sullivan (CA)
09:25
From photon to proton: what’s in it for head and neck cancer patients?
Volker Budach (DE)
09:50
Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?
Hisham Mehanna (UK)
10:15
Break and poster viewing
10:45
Treatment intensification in LA-SCCHN: what are the options and for who?
Jan Vermorken (BE)
11:10
Immune checkpoint inhibitors in the curative setting: preclinical and clinical data
Jean-Pascal Machiels (BE)
11:35
Targeting molecular/minimal residual disease using novel technologies and clinical trials design
Lillian Siu (CA)
13:30
Lunch and sponsored symposium
Session 3: Recurrent and/or metastatic (R/M) SCCHN
Chair: René Leemans
14:30
Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?
Petr Szturz (CH)
15:00
Patterns of response to immune oncology drugs: how relevant are they in SCCHN?
Amanda Psyrri (GR)
15:20
The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN
Daan Nevens (BE)
15:45
Break and poster viewing
16:15
Proffered paper session
Chaired by Jean-Pascal Machiels
17:15
Keynote lecture: Real world evidence in head and neck cancer
Anil D’Cruz (UICC president)
Session 4: Special topics
Chair: Brian O’Sullivan (CA)
09:00
Pathology driven treatment of skull base tumors
Piero Nicolai (I)
09:25
Modern day reconstruction of facial bones
Sat Parmar (UK)
09:50
Carcinoma of unknown primary: diagnostics and the potential of transoral surgery
René Leemans (NL)
10:15
Coffee break
10:45
New developments in surgery for malignant salivary gland tumors
Jeroen Meulemans (BE)
11:10
New systemic therapies in salivary gland cancer
Athanassios Argiris (GR)
11:35
Exercise and nutrition interventions in head and neck cancer
Paolo Bossi (I)
12:00
Telehealth intervention in head and neck cancer patients: a promise?
Irma Verdonck-de Leeuw (NL)
12:25
General discussion
13:00
Adjourn